• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Cardiology

Thrombolysis for pulmonary embolism may benefit younger patients, harm older patients

byAshmita BanerjeeandBrittany Hasty, MD
June 18, 2014
in Cardiology, Emergency, Pulmonology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. Thrombolysis for pulmonary embolism (PE) in intermediate-risk patients decreased mortality in patients younger than 65 years but not in older patients when compared with anticoagulation. 

2. Thrombolysis increased risk of major bleeding in intermediate-risk patients older than 65 years but not in younger patients. 

Evidence Rating Level: 1 (Excellent)       

Study Rundown: Pulmonary embolism (PE) can be treated with thrombolysis or anticoagulation. Currently, there is no consensus regarding the risks and benefits of thrombolysis relative to anticoagulation. This study evaluated efficacy and safety of thrombolytic use based on a meta-analysis of randomized control trials (RCTs), predominantly patients who were hemodynamically stable with right ventricular (RV) dysfunction (intermediate risk of PE). This study found that in patients older than 65 years, thrombolysis does not improve survival and increases risk of major bleeding. For younger patients there is a survival benefit and no association with increased risk of bleeding. In the complete cohort of patients, thrombolysis decreased the risk of recurrence but increased the risk of intracranial hemorrhage (ICH).

This study has significant limitations. Only mean ages were reported in the RCTs, thereby limiting the reliability of the age-based subgroup analysis. The results cannot be reliably associated with patients with lower and higher risks of PE because of the small sample sizes for these patients. The definition of ‘major bleeding” and doses of thrombolytics vary amongst RCTs included in the study and mortality was evaluated at different end-points. While this study suggested that thrombolysis have a net benefit for younger patients and net harm for older patients, further research is required before incorporating these results at the bedside.

Click to read the study, published today in JAMA

Relevant Reading: Systemic thrombolytic therapy for acute pulmonary embolism: a systematic review and meta-analysis

RELATED REPORTS

Venous thromboembolism rates in hospitalized children continue to rise

Rivaroxaban prophylaxis improves clinical outcomes in high-risk patients hospitalized with COVID-19

The use of a diagnostic strategy with age-adjusted D-dimer thresholds was non-inferior in risk-stratifying for thromboembolic events in emergency department patients with suspected pulmonary embolism

In-Depth [systematic review and meta-analysis]: This study included 16 RCTs through April 2014 that compared the use of thrombolysis with the use of traditional anticoagulants (n = 2115) including 8 trials that only enrolled intermediate-risk patients (n = 1775). Primary outcomes were all-cause mortality and risk of major bleeding. Mean follow-up period was 81.7 days. Thrombolytic therapy was associated with significantly lower all-cause mortality (OR, 0.53; 95% CI, 0.32-0.88) but increased risk of major bleeding (OR, 2.73; 95% CI, 1.91-3.91) relative to anticoagulative therapy. This was also noted in the trials with only intermediate-risk patients including the post-2009 analysis. In patients older than 65 years there was no difference in all-cause mortality but they did have a greater risk of major bleeding (OR, 3.10; 95% CI, 2.10-4.56) compared to younger patients who showed no significant increase in risk of bleeding (P= 0.89). All patients who received thrombolysis had decreased the risk of recurrent pulmonary embolism (PE) (P= 0.003) but increased risk of intracranial hemorrhage (ICH) (P= 0.002).

Image: CC/Heilman 

More from this author: Acamprosate, naltrexone may be effective for alcoholic disorders,Paliperidone and haloperidol demonstrate comparable results in schizophrenia [ACLAIMS trial],Addition of insulin to metformin in Type 2 Diabetes may increase risk of mortality 

©2012-2014 2minutemedicine.com. All rights reserved. No works may be reproduced without expressed written consent from 2minutemedicine.com. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors, editors, staff or by 2minutemedicine.com. PLEASE SEE A HEALTHCARE PROVIDER IN YOUR AREA IF YOU SEEK MEDICAL ADVICE OF ANY SORT.  

Tags: pulmonary embolism
Previous Post

Affordable Care Act: Improved health, lower costs in youth with dependent coverage

Next Post

Regional central nervous damage associated with fatigue in multiple sclerosis

RelatedReports

siRNA against antithrombin alleviates symptoms of hemophilia [PreClinical]
Chronic Disease

Venous thromboembolism rates in hospitalized children continue to rise

February 14, 2022
Most anticoagulants for venous thromboembolism similarly effective
Hematology

Rivaroxaban prophylaxis improves clinical outcomes in high-risk patients hospitalized with COVID-19

January 18, 2022
Quick Take: Hospital volume and outcomes for acute pulmonary embolism
Emergency

The use of a diagnostic strategy with age-adjusted D-dimer thresholds was non-inferior in risk-stratifying for thromboembolic events in emergency department patients with suspected pulmonary embolism

December 10, 2021
Thrombophilia-associated stillbirth risk appears limited to factor V Leiden
Emergency

Utility of D-dimer testing and modified thresholds for ruling out pulmonary embolism in COVID-19 patients

October 13, 2021
Next Post

Regional central nervous damage associated with fatigue in multiple sclerosis

Mediterranean diet linked to reduced diabetes risk in high risk cardiovascular patients

No link between antidepressant use in pregnancy and fetal cardiac abnormalities

Tofacitinib superior to methotrexate monotherapy for rheumatoid arthritis

Tofacitinib superior to methotrexate monotherapy for rheumatoid arthritis

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

Get 2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • #VisualAbstract: Severe actinic keratosis and need for additional treatment are markers for an increased risk of cutaneous squamous cell carcinoma
  • Virtual yoga and meditation intervention may be associated with increased health-related quality of life
  • Wellness Check: Mental Health
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.